Introduction
Beta blockers have been shown to reduce mortality in patients with congestive heart failure and impaired left-ventricular systolic function. [1] [2] [3] [4] Long-term treatment in patients with impaired left-ventricular (LV) function can reduce the symptoms of heart failure, improve the clinical status of patients, and enhance the quality of life. [5] [6] [7] [8] [9] [10] [11] [12] One advantageous mechanism of beta-blocker therapy in patients with heart failure (HF) is its ability to reduce the resting heart rate. Several studies have established that an elevated resting heart rate is a prognostic factor for cardiovascular events and mortality in healthy individuals 13, 14 and in patients with hypertension, 15 myocardial infarction, 16 stable coronary artery disease, 17, 18 and HF. 19, 20 Subanalyses of randomized controlled trials in which patients with HF were treated with beta blockers demonstrated a direct relationship between the degree of resting heart rate reduction and a decline in mortality and other major cardiovascular events. [20] [21] [22] In addition, a metaregression analysis of beta-blocker HF trials has shown that the magnitude of survival benefit seen with beta blockers is associated with the level of heart rate reduction and not with the dosage of beta-blocker administered. 23 Heart rate reduction, therefore, may be an important treatment target for patients with HF.
Ivabridine is an I f current inhibitor and mediates a reduction in heart rate through its action on this channel in pacemaker cells of the sinus node 24 and has been shown to benefit patients with HF. Inhibition of the I f channel results in a reduced sodium and potassium ion flow, which delays the slow diastolic depolarization phase of the sinus node cell action potential, thus lowering the heart rate. The exclusive heart-rate lowering properties of ivabridine were assessed in patients with heart failure with a reduced left-ventricular ejection fraction (HFrEF) in the systolic heart failure treatment with the I f inhibitor ivabradine trial (SHIFT) study. 25 The primary composite endpoint of cardiovascular death or hospital admission for worsening HF was significantly reduced in those patients receiving ivabridine. 26 Ivabridine has now been incorporated into the HF practice guidelines in Europe, 27 UK, 28 and more recently, in Canada. 29 The aim of this study was to perform an extensive review of pharmacologic and device utilization, with a focus on beta-blocker therapy, in a single-center Canadian community hospital heart function clinic since this has not been undertaken previously. In addition, this study sought to determine the proportion of patients in a typical community heart function clinic who would potentially benefit from the addition of relatively new pharmacological therapies available for the treatment of heart failure, namely ivabridine and sacubitril-valsartan.
Methods study population
In this analysis, we performed a retrospective cross-sectional analysis of all patients followed in the Oakville Trafalgar Memorial Hospital's (OTMH) outpatient heart function clinic in Oakville, ON, Canada, as of April 30, 2014. Only patients treated in the clinic for at least a 12-month period were included in the analysis to allow the titration of pharmacotherapy and implantation of device therapy, if indicated. Patients were assessed with respect to beta-blocker use and dose, demographics, clinical history, comorbidities, and resting heart rate. A subgroup of patients within the clinic who would have met the inclusion criteria for enrollment in the SHIFT study 25 (left-ventricular ejection fraction [LVEF] .35%, sinus rhythm, New York Heart Association [NYHA] II-IV) and the Prospective Comparison of angiotensin receptor-neprilysin inhibitor (ARNI) with angiotensin-converting enzyme inhibitor (ACEI) to determine impact on global Mortality and Morbidity in Heart Failure (PARADIGM-HF) study 30 (LVEF ,40%, NYHA II-IV, glomerular filtration rate [GFR] .30 mL/min) were also analyzed. A review of the adherence to other guideline-recommended pharmacotherapies was also carried out. Patients with implantable cardiodefibrillators and pacemakers were included in the overall analysis. Since this was a review of all patients who were followed in the clinic for at least 1 year and meeting the diagnosis of chronic heart failure (CHF), there were no designated exclusion criteria.
This study conformed to the principles outlined in the 1964 Declaration of Helsinki, and approval from the OTMH Ethics Committee was obtained before initiating this study. A waiver of patient consent was granted from the OTMH Ethics committee for this retrospective analysis.
Data collection
Data were collected retrospectively from patient charts in the OTMH's heart function clinic. All patients meeting the diagnosis of CHF based on the Canadian Cardiovascular Society guidelines were included. General information, including patient demographics, cardiac history, and previous cardiac investigations, was obtained from the clinic charts. The etiology of CHF was classified as ischemic or nonischemic based on the patient's clinical history and ancillary investigations. Functional assessments were categorized according to the NYHA classification. Prescribed cardiac medications, including beta blockers and their dose, ACEI/angiotensin receptor blocker (ARB), antiplatelet agents, anticoagulants, lipid-lowering therapy, digoxin, diuretics, mineralcorticoid receptor antagonists (MRAs), and antiarrhythmics, were obtained from the patient's clinic chart. Data from patients not treated with a beta blocker due to a contraindication or intolerance were recorded, and the reason for the absence of therapy was documented. Follow-up information on vital status, all-cause admissions and heart failure admissions were obtained from the patient's clinic chart and OTMH's record. Resting heart rates were assessed by the patient's 12-lead electrocardiogram performed during the routine visits to the clinic. LVEFs were determined through the biplane disk summation method (Simpson's rule) by two-dimensional echocardiography or by a multigated acquisition scan.
statistical analysis
Patient characteristics are shown as the absolute number of patients and percentages, median and quartiles, or mean and standard deviation as appropriate. Patients meeting the SHIFT trial criteria were stratified by heart rate with their most recent heart rates either 70 bpm or ,70 bpm. An additional group was stratified with their most recent heart rates either 75 bpm or ,75 bpm. The groups were compared using the chi-square test or Fisher's exact test and Student's t-test or Mann-Whitney U-test, as appropriate. The outcomes of death, all-cause admission to hospital, and HF admission to hospital were analyzed for the whole cohort and those meeting the SHIFT criteria. Unadjusted 23-month survival of the entire cohort was estimated by the Kaplan-Meier method. In addition, unadjusted 23-month survival stratified by heart rate and LVEF were estimated by the Kaplan-Meier method.
Results
In total, 371 patients who were active participants in the OTMH's heart function clinic for 12 months preceding April 30, 2014, were assessed with respect to their treatment dosages of beta blockers, their demographic and clinical profiles, and their resting heart rate. An assessment of other guidelinerecommended pharmacotherapies and device therapy was also carried out. Table 1 illustrates the demographic and clinical characteris tics of the overall cohort of patients treated in the OTMH's heart function clinic. The optimized pharmacotherapy and device therapy provided to patients in the clinic are outlined in Tables 2 and 3 .
A detailed description of beta-blocker use in all patients within the heart function clinic (87.3%) and those with HFrEF (92.5%) is displayed in Table 4 . Table 4 and Figure 1 also highlight the utilization of the three beta blockers specifically indicated for the treatment of HF among all patients and those with HFrEF. Table 4 and Figure 2 demonstrate the percentage target dose achieved among the beta blockers specifically indicated for the treatment of HF. The mechanism of intolerance for those patients who were not prescribed a beta blocker is also outlined in Table 4 .
Of the overall studied population, 51 (13.7%) patients would have fulfilled the criteria for randomization into the SHIFT trial (LVEF #35%, sinus rhythm, NYHA II-IV). Detailed characteristics of study patients who would have met the inclusion criteria are displayed in Table 5 according to the categories of heart rate. Patients with heart rates .70 bpm were younger and exhibited a significantly poorer rates 75 bpm had a significantly poorer NYHA functional class (P=0.009) and a significantly less beta-blocker use (P=0.028). Tables 7 and 8 highlight the 23-month outcomes of patients who would have fulfilled the SHIFT criteria when stratified with a resting heart rate ,70 bpm or 70 bpm. There was no difference in mortality between the groups. There was a trend for a reduction in HF and all-cause admissions for patients with a heart rate ,70 bpm. An additional analysis of outcomes was also carried out when stratifying patients with a resting heart rate ,75 bpm or 75 bpm. There was a significant decrease in the combination of death and HF admission (P=0.016) and death and all-cause admission (P=0.020). In addition, there was a trend toward a decrease in mortality (P=0.14) in patients with a heart rate ,75 bpm.
A total of 105 (28.1%) patients in this community heart function clinic would have met criteria for enrollment in the PARADIGM-HF study (LVEF ,40%, NYHA II-IV, GFR .30 mL/min) and, therefore, met criteria for the initiation of sacubitril-valsartan.
Admission to OTMH for any cause was assessed from May 1, 2014, to March 20, 2016, and is displayed in Table 9 . Patients admitted to hospital for any cause over this time period, were significantly older and had a worse NYHA functional class. Clinic patients admitted with a primary diagnosis of HF over this same time period are highlighted in Table 10 . This population had a significantly poorer NYHA functional class (P=0.0004) and were older (P=0.030) than study patients who were not admitted with heart failure.
Mortality was assessed over a 23-month period of all patients within the clinic as of April 30, 2014. The overall mortality rate over this period was 20.2% ( Figure 3 ). Mortality stratified by heart rate ,70 bpm and 70 bpm and LVEF ,50% and 50% is displayed in Figure 4 . 
Percentage of patients
Bisoprolol Figure 2 Target dose achieved for beta blockers prescribed to study patients. provided to the entire clinic population, comprised of patients with both preserved and reduced LVEFs. Adherence to guideline-recommended pharmacotherapy specifically for heart failure patients with a reduced left-ventricular ejection was particularly high. In this subgroup of patients, 86.1% of eligible patients were treated with ACEI/ARBs, 100% of eligible patients received beta blockers and 61.9% of eligible patients received MRAs (Table 3 ). Our single-center community hospital-based heart function clinic pharmacotherapy performance exceeded the median performance in American and European ambulatory heart failure registries. In the IMPROVE-HF 31 and PIN-NACLE 32 studies in which heart failure management was assessed in outpatient American cardiology practices, the rate of ACEI/ARB use was 80% in IMPROVE-HF and 79% in PINNACLE. The rate of beta-blocker use was 86% in IMPROVE-HF and 89% in PINNACLE. MRA use was not reported in the PINNACLE study; however, in the IMPROVE-HF study, MRA use was 34.5% at baseline and increased to 60.3% in 24 months following the performance improving interventions from the trial coordinating center. Our adherence to pharmacotherapy also exceeded the performance registries in Europe. In an assessment of CHF management in six European countries, the use of ACEI/ARB, beta blockers, and MRAs were 87%, 53%, and 28%, respectively. 33 An assessment of the number and composition of HF clinics in Ontario, Canada, was recently carried out; however, an evaluation of HF guideline adherence from these centers or another single-center community hospital in Canada has not been reported previously. 34 Thus far Canadian outpatient HF management data have been limited to abstract publications. 35, 36 This study is the first to reflect the contemporary care in a single nonuniversity-based Canadian outpatient heart function clinic and highlights the excellent adherence to guideline-recommended therapy. The high level of adherence in our clinic is related to the multidisciplinary approach and the incorporation of components that have been shown to be effective in a HF clinic program. This model of care has been shown to prolong survival, reduce hospitalizations, and improve quality of life. 37 Elements important to patient outcome include a team approach to patient care led by cardiologists with an expertise in heart failure, cardiac nurses, and pharmacists; medication optimization and development of an individualized treatment strategy; patient and family education support; promotion of lifestyle modifications, including the assessment of daily weights, compliance of medication , and avoidance of dietary indiscretion; timely clinic follow-up; and a mechanism to permit patient-initiated access to the clinic for support, if required. 37 Beta blockers have been shown to reduce cardiovascular morbidity and mortality in patients with congestive heart failure and a reduced LVEF. [38] [39] [40] [41] [42] [43] [44] Several registries and singlecenter studies have assessed the utilization of beta-blocker therapy in outpatient heart function clinics. [45] [46] [47] [48] [49] [50] Despite the effectiveness of beta blockers in the treatment of heart failure, many patients have relative contraindications or experience significant side effects, resulting in a poor compliance or discontinuation. 51 Even in the landmark clinical trials involving beta-blocker therapy in patients with heart failure, only 80% of patients were able to achieve the target dose, and a significant proportion of those could not maintain that dose over time. 38, 39, 52, 53 In our analysis, we were able to show that the overall use of beta blockers exceeded 87%, while 100% of patients without a documented contraindication or intolerance received therapy (Tables 3 and 4 ). In comparison to the randomized clinical trials, however, a much smaller proportion of our patient population (18.9%) were able to tolerate the target doses of the bisoprolol, carvedilol, or metoprolol. Similar shortfalls in achieving guideline-recommended prescription doses have been observed elsewhere outside of the clinical trial setting. 45, 48, 49 This clearly demonstrates the clinical need for additional heart rate-lowering therapy that is well tolerated and effective in HF.
In the SHIFT study, ivabridine significantly reduced the major cardiovascular outcomes in patients with HF who were in sinus rhythm with a heart rate .70 bpm. 25 An analysis of baseline heart rate in SHIFT showed greater benefits, including all-cause mortality, among patients with a baseline heart rate 75 bpm. Based on these results, national and international guidelines from Canada, the UK, and the European Medicines Agency recommend the use of ivabridine for the treatment of patients with HF (NYHA class II-IV) and systolic dysfunction who are in sinus rhythm and receiving guideline-based background therapy, including a beta blocker. [27] [28] [29] There are, however, differences among the three HF guidelines with respect to the clinical phase, background medical therapy, and baseline heart rate that would prompt the initiation of ivabridine. Ivabridine has been approved for the treatment of HF in US, but it has not yet been incorporated into HF practice guidelines. In contrast, the recently updated Canadian HF guidelines recommend the use of ivabridine for select patients with HF; however, at the moment, it awaits regulatory approval in Canada and has therefore not yet entered into clinical practice.
Based upon the SHIFT criteria it would be expected that a select group of patients in our clinic (13.7%) would benefit from ivabridine should it be approved for use in Canada. (Tables 5 and 6 ). In fact, when SHIFT eligible patients were stratified in our cohort with a heart rate of ,75 bpm or 75 bpm, there was a significant reduction in the combination of death/HF admissions and death/all-cause admissions ( Tables 7 and 8 ). The proportion of patients who may be eligible for treatment with ivabridine in this study is similar to the 14% of patients deemed eligible from a community HF clinic analysis in England. 54 The number of eligible patients may be even higher as suggested by an analysis from an HF nurse-managed community care initiative in Scotland that demonstrated that 25 Interestingly, a total of 52.8% of patients in this community hospital-based heart function clinic had a diagnosis of either paroxysmal or permanent AF. The high prevalence of AF is one major reason why more patients in this study would not meet criteria for the initiation of ivabridine. Since both AF and HF occur frequently, it is not surprising that these two conditions coexist among many patients in the clinic. In fact, HF and AF share a number of common risk factors, including hypertension, diabetes mellitus, ischemic heart disease, and valvular heart disease. 56 The prevalence of AF in patients with systolic left-ventricular dysfunction and HF has been shown to range from 6% in patients who are asymptomatic or with minimal symptoms 57 to between 15% and 35% in patients with NYHA class II-IV symptoms. 52, [58] [59] [60] [61] [62] [63] [64] [65] In addition, the prevalence of AF has been shown to be greater in HF patients with preserved ejection fractions when compared to those with left-ventricular systolic dysfunction. 66, 67 In our experience, the prevalence of AF in patients with preserved left-ventricular function (EF .50%) was 49.0% and was, therefore, nearly identical to those with a reduced LVEF. Importantly, adherence to guideline-recommended therapy in our clinic extended also to the treatment of patients with AF. A substantial proportion of eligible patients were prescribed an anticoagulant (90.8%) as recommended by the current Canadian Cardiovascular Society guidelines. 68 An additional pharmacological option for the treatment of heart failure, neprilysin inhibition, was recently approved for use in Canada and has also been incorporated into the updated Canadian Cardiovascular Society HF guidelines. 29 Inhibition of neprilysin, a neutral endopeptidase, increases the level of vasoactive peptides, including natriuretic peptides, bradykinin, and adrenomedullin. 69 The products of neprilysin inhibition counter neurohormonal activation that can serve to minimize vasoconstriction, sodium retention, and maladaptive remodeling. When the neprilysin inhibitor sacubitril was combined with the angiotensin receptor antagonist valsartan in the PARADIGM-HF study, there was a significant reduction in the primary endpoint of cardiovascular death or heart failure hospitalization. 30 In our analysis, 28.3% of patients within the clinic would have met the criteria for enrollment into the PARADIGM-HF study (LVEF ,40%, NYHA II-IV, GFR .30 mL/min). This represents a significant proportion of patients who may potentially benefit from sacubitril-valsartan therapy.
Following a diagnosis of HF, mortality estimates are 50% and 10% at 5 years and 10 years, respectively. 70 The mortality of patients treated in a Canadian single-center community HF clinic has not been explored previously. We determined that at our center, 1-year mortality was ∼13%, and the 23-month mortality was ∼20% (Figure 3 ). Our 1-year value is very similar to the most recently published HF mortality in the province of Ontario, Canada (2007), which estimated an unadjusted 1-year mortality of 15.8% 71 among outpatients with HF. We found no statistical difference in mortality when patients were stratified according to their LVEF or resting heart rate (Figure 4) ; however, this sub-analysis was limited by the small number of patients included in the cohort.
Study limitations
This cohort study is limited by the characteristic shortcomings of a registry. The value of this registry, however, is the fact that the entire complement of the heart function clinic was included in the analysis. Even patients who would have been typically excluded in a conventional randomized controlled HF study were subjected to study. In addition, we did not exclude patients receiving other chronotropic agents that would be expected to decrease the resting heart rate, such as digitalis and nondihydropyridine calcium channel blockers. Furthermore, unlike a randomized controlled study in which compliance can be assessed, we were unable to ensure the adherence and persistence of pharmacotherapy. Hospitalizations at other institutions apart from the three hospitals that comprise Halton Healthcare Services were not captured, and therefore, the reported event rates may be underestimated. Finally, the heart rate assessments were taken from the 12-lead ECG, as was done in the randomized clinical trials. Ambulatory ECG monitoring may have provided a more comprehensive assessment of heart rate control.
Conclusion
In this nonrandomized cohort of heart failure patients in a community-based heart function clinic, the adherence to guideline-recommended pharmacotherapy was high. In particular, every patient eligible for beta-blocker therapy received treatment; however, target doses of beta blockers could not be achieved in many patients. A smaller cohort of these patients with a heart rate 70 bpm and fulfilling the SHIFT trial criteria (LVEF ,35%, sinus rhythm, NYHA II-IV) were identified. Since titration of beta blockers to the doses recommended by landmark clinical trials and national guidelines is often not possible, the addition of a selective heart rate lowering medication, such as ivabridine, may improve the outcomes in a number of patients with HF in this community setting. In addition, this analysis identified a substantial proportion of patients who may also benefit from the initiation of the other relatively new pharmacologic treatment for HF, sacubitril-valsartan.
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